| Grant number: | 16/00468-0 |
| Support Opportunities: | Regular Research Grants |
| Start date: | December 01, 2016 |
| End date: | November 30, 2018 |
| Field of knowledge: | Health Sciences - Medicine - Pathological Anatomy and Clinical Pathology |
| Principal Investigator: | Luiz Felipe Domingues Passero |
| Grantee: | Luiz Felipe Domingues Passero |
| Host Institution: | Instituto de Biociências (IB-CLP). Universidade Estadual Paulista (UNESP). Campus Experimental do Litoral Paulista. São Vicente , SP, Brazil |
| Associated researchers: | João Henrique Ghilardi Lago |
Abstract
Leishmaniasis are diseases caused by parasitic protozoal of Leishmania genus. There are different species able to infect humans and they induce distinct clinical forms, and surprisingly the therapy is based on two drugs that induce serious side effects in patients. Therefore, it is necessary and urgent searching for new candidates to the therapy. Thus, the aim of this project is to characterize the leishmanicidal action (in vitro and in vivo) of pure and synthetic compounds. The drugs Butenafine, Naftifine, Fenticonazole and Rosuvastatin will be commercially purchased. Pure natural products will be purified through bioprospection procedures from crude extract produced with the leaves of the following vegetal species: Euphorbia tirucalli, Gochnatia polymorpha, Alchornea glandulosa, Ruta graveolens and Solanum americanum. Pure compounds presenting low cytotoxic activity and antileishmanial activity similar or higher than Amphotericin B and/or miltefosine, will be evaluated concerning their action mechanisms, and will be selected for in vivo studies, that will be conducted in animal models of tegumentar and visceral leishmaniasis. In these animals, parasitological, pathological and immunological studies will be conducted. In previous studies, we demonstrated the efficacy of ursolic acid in visceral and tegumentar leishmaniasis, and for this reason, this compound will be loaded in nanocarriers in the attempt to increase its therapeutic effect in animal models. Finally, the main purpose of this project is to characterize new synthetic and natural prototypes with leishmanicidal action in vitro and in vivo, aiming at increasing the current therapeutic arsenal of leishmaniasis. (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |